Moderator of 2 Sessions
Session Description:
A multi-disciplinary discussion on simplifying automated insulin delivery systems from pump selection and setting expectations to initiation and optimization, supported with patient insights and the first release of Omnipod® 5 System real-world evidence
Presenter of 7 Presentations
Supporting Pump Selection & Overview of the Omnipod® 5 System (ID 1165)
Panel Discussion - The Future of Diabetes: Time in Range & CGM (ID 1200)
Q&A (ID 1126)
Q&A (ID 1168)
Dexcom G7 Unique Features and Correlational Improvements in Glycemic Control (ID 1122)
IS024 - - In the United Kingdom (ID 217)
Abstract
Abstract Body
AID experience in the real-world in the United Kingdom
Background
Hybrid closed loop (HCL) technology automates insulin delivery and improves outcomes in people living with Type 1 diabetes. We report real-world outcomes from adults with Type 1 diabetes with raised HbA1c despite insulin pump therapy and flash glucose monitoring.
Methods
A national clinical audit programme collected routine, anonymised clinical data submitted to a secure online tool. Reported outcomes include HbA1c, key glucose sensor metrics; Diabetes Distress Score; Gold Score; event rates (hospital admissions, paramedic callouts and severe hypoglycaemia) and user opinion of HCL.
Results
Follow up data were available from 520 HCL users; median age 40 (IQR 29-50) years, 67% female, mean diabetes duration of 21 (IQR 15-30) years, 85% white British. Baseline HbA1c 78.9±9.1mmol/mol [9.4±0.8%] reduced to 62.1±9.1mmol/mol [7.8±0.8%] at 5.1 (IQR 3.9-6.6) months median follow up. Mean adjusted HbA1c reduced by -18.1mmol/mol (95% CI -16.5, -19.6; P<0.001) [1.7% (95% CI 1.5, 1.8, P<0.001)]. Time in range (3.9-10mmol/l) increased from 34.2% to 61.8% (P<0.001), time below range (<3.9mmol/l) reduced from 2.1% to 1.6% (P<0.001). The proportion reporting diabetes-related distress reduced from 69.0% to 22.5%(P=0.001). Gold score reduced from 2.2 to 1.6 (P<0.001). Almost all (96.3%, 549/570) would recommend HCL to others with diabetes; 94.7% (540/570) reported that the system had a positive impact on their quality of life. No significant increases in hospital admissions/paramedic callouts were found.
Conclusion
The NHS England pilot of HCL therapy led to substantial improvements in HbA1c, time in range and time below range over 5 months of follow up. The prevalence of diabetes related distress improved. Almost all reported a positive impact on quality of life and would recommend the use of HCL system to other people living with diabetes.
IS061 - Helping adults choose a safe and effective CGM in light of new national guidance (ID 277)
Abstract
Abstract Body
There is growing evidence to support the use of continuous glucose monitoring in people living with diabetes. As such, in the UK the National Institute for Clinical Excellence (NICE) now recommend that all people living with Type 1 diabetes, and sub-groups of people with insulin treated Type 2 diabetes should have access to interstitial glucose monitoring. In those with Type 1 diabetes the choice should ideally be based on individual preferences, considering the needs, characteristics, and functionality of the devices. Some of the factors to be considered for individuals with Type 1 diabetes include device accuracy, predictive alerts/alarms, dexterity, hypoglycaemia fear, psychosocial factors, need for use as part of a closed loop, calibration, data sharing, hypoglycemia awareness and cost. This lecture will consider the practical considerations above, alongside available evidence to support informed, collaborative decision making when deciding on the optimal continuous glucose monitoring solution.